186 related articles for article (PubMed ID: 37625037)
1. Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.
Bai S; Kang Y; Chen W; Xie H; Zhang L; Lv M; Wang J; Wu J; Zhao W
Viral Immunol; 2023 Oct; 36(8):526-533. PubMed ID: 37625037
[TBL] [Abstract][Full Text] [Related]
2. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
4. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Amarilla AA; Modhiran N; Liang B; Li Z; Wijesundara DK; Lackenby JA; Griffin P; Bennet JK; Hensen L; Zhang W; Nguyen THO; Tran MH; Tapley P; Barnes J; Reading PC; Kedzierska K; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
EBioMedicine; 2023 Nov; 97():104842. PubMed ID: 37865043
[TBL] [Abstract][Full Text] [Related]
6. Alum/CpG adjuvant promotes immunogenicity of inactivated SARS-CoV-2 Omicron vaccine through enhanced humoral and cellular immunity.
Zheng X; Yang R; Zhao Y; Zhang Y; Yuan G; Li W; Xiao Z; Dong X; Ma M; Guo Y; Wang W; Zhao X; Yang H; Qiu S; Peng Z; Liu A; Yu S; Zhang Y
Virology; 2024 Jun; 594():110050. PubMed ID: 38479071
[TBL] [Abstract][Full Text] [Related]
7. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S; Fakharzadeh S; Karimi P; Hafizi M; Jamaati H; Hassanzadeh SM; Khorasani A; Mahdavi M; Nazaran MH
Viral Immunol; 2023; 36(6):409-423. PubMed ID: 37506342
[TBL] [Abstract][Full Text] [Related]
8. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
[TBL] [Abstract][Full Text] [Related]
9. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
11. The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Yang J; Li B; Yang D; Wu J; Yang A; Wang W; Lin F; Wan X; Li Y; Chen Z; Lv S; Pang D; Liao W; Meng S; Lu J; Guo J; Wang Z; Shen S
Vaccine; 2023 Sep; 41(41):6064-6071. PubMed ID: 37640568
[TBL] [Abstract][Full Text] [Related]
12. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
Front Immunol; 2022; 13():966098. PubMed ID: 35979361
[TBL] [Abstract][Full Text] [Related]
13. Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice.
Luan N; Wang Y; Cao H; Lin K; Liu C
J Med Virol; 2022 May; 94(5):2250-2258. PubMed ID: 35112364
[TBL] [Abstract][Full Text] [Related]
14. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
15. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
16. Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine.
Richmond PC; Hatchuel L; Pacciarini F; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
J Infect Dis; 2021 Nov; 224(10):1699-1706. PubMed ID: 34480575
[TBL] [Abstract][Full Text] [Related]
17. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
[TBL] [Abstract][Full Text] [Related]
18. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
19. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.
Honda-Okubo Y; Barnard D; Ong CH; Peng BH; Tseng CT; Petrovsky N
J Virol; 2015 Mar; 89(6):2995-3007. PubMed ID: 25520500
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
